Sun Pharmaceutical Q3 earnings today: Here's what to expect

Sun Pharmaceutical Industries’ revenues are expected to grow around 5.6 percent; Earnings before interest, taxes, depreciation, and amortization (Ebitda) is expected to decline about 20 percent with margins coming in at about 21 percent with a profit decline of around 15 percent.

Sun Pharmaceutical's numbers are going to be impacted because of high base as well as Taro which was a disappointment this quarter. In Q3FY19 the revenue was up about 16 percent, Ebitda was up 28 percent and profit stood at Rs 1,241 crore.

Now the street is expecting some tapering in the domestic formulation business. Taro reported disappointing earnings in the US, which will weigh on Sun's US portfolio.